Journal of Thrombosis and Thrombolysis

, Volume 38, Issue 1, pp 98–104 | Cite as

Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital

Article

Abstract

The most common indication for treatment with warfarin is the prevention of ischemic stroke in patients with atrial fibrillation. Time in therapeutic range (TTR) is an important tool to evaluate the quality of anticoagulation treatment. The aim of this study was to investigate the quality of treatment and the incidence of bleeding complications in patients on warfarin treatment treated by the anticoagulation clinic in Helsingborg. This is the first study that has specifically focused on the spontaneous reporting of bleeding complications in a real-world population. A total of 4,400 patients with a total of 8,394 patient years were registered, in the database Journalia AVK, during the time period November 1, 2007 to November 1, 2010. The mean age was 72 years. TTR was 73.3 % for the whole population. 421 patients suffered from haemorrhagic events. The frequency of major and fatal bleedings and intracranial haemorrhage (ICH) were 1.6, 0.2 and 0.5 % per patient-year, respectively. A correlation between age and severe bleeding (major, fatal and ICH) (p = 0.003) was seen, but no correlation between gender and severe bleeding (p = 0.27). In 60 out of 455 bleeding events the complication had been reported to the anticoagulation clinic. At the anticoagulation clinic in Helsingborg the quality of warfarin treatment is good compared to previous results described in the literature, with regards to bleeding complications and efficacy. However, in our study, we confirm that the spontaneous reporting of bleeding complications related to warfarin is inadequate, and that review of patient records is needed to assure proper follow-up.

Keywords

Warfarin TTR Atrial fibrillation Spontaneous reporting Bleeding complications 

References

  1. 1.
    Cavallini A, Fanucchi S (2008) Warfarin-associated intracerebral hemorrage. Neurol Sci 29:266–268CrossRefGoogle Scholar
  2. 2.
    Nationella riktlinjer för hjärtsjukvård. Socialstyrelsen 2008. ISBN: 978-91-85483-96-9Google Scholar
  3. 3.
    Socialstyrelsen. Socialstyrelsens riktlinjer för vård av blodpropp/venös tromboembolism 2004. Faktadokument och beslutsstöd för prioriteringar. http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attchments/10270/2004-102-3-20041023.pdf
  4. 4.
    Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use. A prevalent adverse effect resulting in regulatory action. Arch Intern Med 167(13):1414–1419PubMedCrossRefGoogle Scholar
  5. 5.
    Wiederman CJ, Stockner I (2008) Warfarin-induced bleeding complications-clinical p resentation and therapeutic options. Thromb Res 122(Suppl. 2):13–18CrossRefGoogle Scholar
  6. 6.
    Go A, Hylek E, Phillips K et al (2001) Prevalence of diagnosed atrial fibrillation in adults. National implications of rytm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (Atria) study. JAMA 285:18CrossRefGoogle Scholar
  7. 7.
    Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment, American college of chest physicians evidence-based clinical practise guidelines (8th edition). Chest 133:257–298CrossRefGoogle Scholar
  8. 8.
    Gottsäter A, Svensson PJ (2010) Klinisk handläggning av venös tromboembolism. Studentlitteratur AB, LundGoogle Scholar
  9. 9.
    Steiner T, Rosand J, Diringer M (2006) Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 37:256–262PubMedCrossRefGoogle Scholar
  10. 10.
    Conolly SJ, Pogue J, Eikelboom J et al (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037CrossRefGoogle Scholar
  11. 11.
    Wieloch M, Själander A, Frykman V et al (2011) Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding and thromboembolic complications from the national quality registry Auricula. Eur Heart J 32:2282–2289PubMedCrossRefGoogle Scholar
  12. 12.
    Palaretti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 348:423–428CrossRefGoogle Scholar
  13. 13.
    Wan Y, Heneghan C et al (2008) Anticoagulation control and prediction of adverse effects in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1:84–91PubMedCrossRefGoogle Scholar
  14. 14.
    Camm AJ, Lip G, DeCaterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–2747PubMedCrossRefGoogle Scholar
  15. 15.
    White HD, Gimber M, Feyzi J et al (2007) Comparizon of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239–245PubMedCrossRefGoogle Scholar
  16. 16.
    Jones M, McEwan P, Morgan C et al (2005) Evaluation of the pattern of treatment, level of anticoagulation control and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 91:472–477PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Connolly SJ, Ezekowitz MD et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151PubMedCrossRefGoogle Scholar
  18. 18.
    van Walraven C, Jennings A, Oake N et al (2006) Effect of setting on anticoagulation control: a systematic review and metaregression. Chest 129:1155–1166PubMedCrossRefGoogle Scholar
  19. 19.
    Wallentin L, Yusuf S, Ezekowitz MD et al (2010) Efficiacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975–983PubMedCrossRefGoogle Scholar
  20. 20.
    Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694PubMedCrossRefGoogle Scholar
  21. 21.
    Rosendaal FR, Cannegieter CC, van der Meer FJ et al (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239PubMedGoogle Scholar
  22. 22.
    Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457CrossRefGoogle Scholar
  23. 23.
    Abdelhafiz AH, Wheeldon NM (2004) Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulant clinic. Clin Ther 26:1470–1478PubMedCrossRefGoogle Scholar
  24. 24.
    Ost D, Tepper J, Mihara H et al (2005) Duration of anticoagulation following venous thromboembolism: a metaanalysis. JAMA 294:706–715PubMedCrossRefGoogle Scholar
  25. 25.
    McConeghy K, Bress A, Wing C (2013) Reports of bleeding-related fatalities with dabigatran and warfarin: an analysis using the Food and Drug Administration adverse events reporting system. American College of Cardiology 2013 Scientific Sessions, San Francisco, 10 March 2013, Abstract 914-8Google Scholar
  26. 26.
    FDA drug safety communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran) http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
  27. 27.
    Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med. doi: 10.1056/NEJMp1302834. http://www.nejm.org
  28. 28.
    Weber JCP (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res 6:1–7Google Scholar
  29. 29.
    Landerfeld SC, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95:315–328CrossRefGoogle Scholar
  30. 30.
    Landerfeld CS (1989) Major bleeding in outpatients treated with warfarin: incidence and predicition by factors known at the start of outpatient therapy. Am J Med 87:144–152CrossRefGoogle Scholar
  31. 31.
    Van der Meer FJM, Rosendaal FR et al (1993) Bleeding comlications in oral anticoagulant therapy. Arch Intern Med 153:1557–1562PubMedCrossRefGoogle Scholar
  32. 32.
    Pisters R, Lane RA, Nieuwlaat K et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with AF. The Euro Heart Survey. Chest 138(5):1093–1100PubMedCrossRefGoogle Scholar
  33. 33.
    Lip Gy, Frison L, Halperin JL et al (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED score. J Am Coll Cardiol 57(2):173–180PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Monica Navgren
    • 1
  • Johan Forsblad
    • 1
  • Mattias Wieloch
    • 2
    • 3
  1. 1.Department of Internal MedicineHelsingborg HospitalHelsingborgSweden
  2. 2.Department of Emergency MedicineSkåne University Hospital MalmöMalmöSweden
  3. 3.Department of Clinical SciencesLund UniversityLundSweden

Personalised recommendations